Elucidation of the human serum albumin (HSA) binding site for the Cu-PTSM and Cu-ATSM radiopharmaceuticals

Nathan E. Basken, Carla J. Mathias, Mark Green

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

The Cu-PTSM (pyruvaldehyde bis(N4-methylthiosemicarbazonato) copper-(II)) and Cu-ATSM (diacetyl bis(N4-methylthiosemicarbazonato) copper(II)) radiopharmaceuticals exhibit strong, species-dependent binding to human serum albumin (HSA), while Cu-ETS (ethylglyoxal bis(thiosemicarbazonato) copper(II)) appears to only exhibit nonspecific binding to human and animal serum albumins. This study examines the structural basis for HSA binding of Cu-PTSM and Cu-ATSM via competition with drugs having known albumin binding sites. Warfarin, furosemide, ibuprofen, phenylbutazone, benzylpenicillin, and cephmandole were added toHSAsolutions at drug:HSA mole ratios from 0 to 8:1, followed by quantification of radiopharmaceutical binding to HSA by ultrafiltration. Warfarin, a site IIA drug, progressively displaced both [ 64Cu]Cu-PTSM and [64Cu]Cu-ATSM from HSA. At 8:1 warfarin:HSA mole ratios, free [64Cu]Cu-PTSM and [ 64Cu]Cu-ATSM levels increased 300-500%. This was in contrast to solutions containing ibuprofen, a site IIIA drug; no increase in free [ 64Cu]Cu-PTSM or [64Cu]Cu-ATSM was observed except at high ibuprofen:HSA ratios, where secondary ibuprofen binding to the IIA site may cause modest radiopharmaceutical displacement. By contrast, and consistent with earlier findings suggesting Cu-ETS exhibits only nonspecific associations, [64Cu]Cu-ETS binding to HSA was unaffected by the addition of drugs that bind in either site. We conclude that the species-dependence of Cu-PTSM and Cu-ATSM albumin binding arises from interaction(s) with the IIA site of HSA.

Original languageEnglish (US)
Pages (from-to)2170-2179
Number of pages10
JournalJournal of Pharmaceutical Sciences
Volume98
Issue number6
DOIs
StatePublished - Jun 2009
Externally publishedYes

Fingerprint

Radiopharmaceuticals
Serum Albumin
Binding Sites
Ibuprofen
Warfarin
Pharmaceutical Preparations
Copper
Albumins
copper pyruvaldehyde bis(N(4)-methylthiosemicarbazone) complex
copper (II) diacetyl-di(N(4)-methylthiosemicarbazone)
Pyruvaldehyde
Diacetyl
Phenylbutazone
Penicillin G
Furosemide
Ultrafiltration

Keywords

  • Albumin
  • Distribution
  • PET
  • Preclinical pharmacokinetics
  • Protein binding

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Elucidation of the human serum albumin (HSA) binding site for the Cu-PTSM and Cu-ATSM radiopharmaceuticals. / Basken, Nathan E.; Mathias, Carla J.; Green, Mark.

In: Journal of Pharmaceutical Sciences, Vol. 98, No. 6, 06.2009, p. 2170-2179.

Research output: Contribution to journalArticle

@article{720ef02eabcd4333826c116709e1df5f,
title = "Elucidation of the human serum albumin (HSA) binding site for the Cu-PTSM and Cu-ATSM radiopharmaceuticals",
abstract = "The Cu-PTSM (pyruvaldehyde bis(N4-methylthiosemicarbazonato) copper-(II)) and Cu-ATSM (diacetyl bis(N4-methylthiosemicarbazonato) copper(II)) radiopharmaceuticals exhibit strong, species-dependent binding to human serum albumin (HSA), while Cu-ETS (ethylglyoxal bis(thiosemicarbazonato) copper(II)) appears to only exhibit nonspecific binding to human and animal serum albumins. This study examines the structural basis for HSA binding of Cu-PTSM and Cu-ATSM via competition with drugs having known albumin binding sites. Warfarin, furosemide, ibuprofen, phenylbutazone, benzylpenicillin, and cephmandole were added toHSAsolutions at drug:HSA mole ratios from 0 to 8:1, followed by quantification of radiopharmaceutical binding to HSA by ultrafiltration. Warfarin, a site IIA drug, progressively displaced both [ 64Cu]Cu-PTSM and [64Cu]Cu-ATSM from HSA. At 8:1 warfarin:HSA mole ratios, free [64Cu]Cu-PTSM and [ 64Cu]Cu-ATSM levels increased 300-500{\%}. This was in contrast to solutions containing ibuprofen, a site IIIA drug; no increase in free [ 64Cu]Cu-PTSM or [64Cu]Cu-ATSM was observed except at high ibuprofen:HSA ratios, where secondary ibuprofen binding to the IIA site may cause modest radiopharmaceutical displacement. By contrast, and consistent with earlier findings suggesting Cu-ETS exhibits only nonspecific associations, [64Cu]Cu-ETS binding to HSA was unaffected by the addition of drugs that bind in either site. We conclude that the species-dependence of Cu-PTSM and Cu-ATSM albumin binding arises from interaction(s) with the IIA site of HSA.",
keywords = "Albumin, Distribution, PET, Preclinical pharmacokinetics, Protein binding",
author = "Basken, {Nathan E.} and Mathias, {Carla J.} and Mark Green",
year = "2009",
month = "6",
doi = "10.1002/jps.21570",
language = "English (US)",
volume = "98",
pages = "2170--2179",
journal = "Journal of Pharmaceutical Sciences",
issn = "0022-3549",
publisher = "John Wiley and Sons Inc.",
number = "6",

}

TY - JOUR

T1 - Elucidation of the human serum albumin (HSA) binding site for the Cu-PTSM and Cu-ATSM radiopharmaceuticals

AU - Basken, Nathan E.

AU - Mathias, Carla J.

AU - Green, Mark

PY - 2009/6

Y1 - 2009/6

N2 - The Cu-PTSM (pyruvaldehyde bis(N4-methylthiosemicarbazonato) copper-(II)) and Cu-ATSM (diacetyl bis(N4-methylthiosemicarbazonato) copper(II)) radiopharmaceuticals exhibit strong, species-dependent binding to human serum albumin (HSA), while Cu-ETS (ethylglyoxal bis(thiosemicarbazonato) copper(II)) appears to only exhibit nonspecific binding to human and animal serum albumins. This study examines the structural basis for HSA binding of Cu-PTSM and Cu-ATSM via competition with drugs having known albumin binding sites. Warfarin, furosemide, ibuprofen, phenylbutazone, benzylpenicillin, and cephmandole were added toHSAsolutions at drug:HSA mole ratios from 0 to 8:1, followed by quantification of radiopharmaceutical binding to HSA by ultrafiltration. Warfarin, a site IIA drug, progressively displaced both [ 64Cu]Cu-PTSM and [64Cu]Cu-ATSM from HSA. At 8:1 warfarin:HSA mole ratios, free [64Cu]Cu-PTSM and [ 64Cu]Cu-ATSM levels increased 300-500%. This was in contrast to solutions containing ibuprofen, a site IIIA drug; no increase in free [ 64Cu]Cu-PTSM or [64Cu]Cu-ATSM was observed except at high ibuprofen:HSA ratios, where secondary ibuprofen binding to the IIA site may cause modest radiopharmaceutical displacement. By contrast, and consistent with earlier findings suggesting Cu-ETS exhibits only nonspecific associations, [64Cu]Cu-ETS binding to HSA was unaffected by the addition of drugs that bind in either site. We conclude that the species-dependence of Cu-PTSM and Cu-ATSM albumin binding arises from interaction(s) with the IIA site of HSA.

AB - The Cu-PTSM (pyruvaldehyde bis(N4-methylthiosemicarbazonato) copper-(II)) and Cu-ATSM (diacetyl bis(N4-methylthiosemicarbazonato) copper(II)) radiopharmaceuticals exhibit strong, species-dependent binding to human serum albumin (HSA), while Cu-ETS (ethylglyoxal bis(thiosemicarbazonato) copper(II)) appears to only exhibit nonspecific binding to human and animal serum albumins. This study examines the structural basis for HSA binding of Cu-PTSM and Cu-ATSM via competition with drugs having known albumin binding sites. Warfarin, furosemide, ibuprofen, phenylbutazone, benzylpenicillin, and cephmandole were added toHSAsolutions at drug:HSA mole ratios from 0 to 8:1, followed by quantification of radiopharmaceutical binding to HSA by ultrafiltration. Warfarin, a site IIA drug, progressively displaced both [ 64Cu]Cu-PTSM and [64Cu]Cu-ATSM from HSA. At 8:1 warfarin:HSA mole ratios, free [64Cu]Cu-PTSM and [ 64Cu]Cu-ATSM levels increased 300-500%. This was in contrast to solutions containing ibuprofen, a site IIIA drug; no increase in free [ 64Cu]Cu-PTSM or [64Cu]Cu-ATSM was observed except at high ibuprofen:HSA ratios, where secondary ibuprofen binding to the IIA site may cause modest radiopharmaceutical displacement. By contrast, and consistent with earlier findings suggesting Cu-ETS exhibits only nonspecific associations, [64Cu]Cu-ETS binding to HSA was unaffected by the addition of drugs that bind in either site. We conclude that the species-dependence of Cu-PTSM and Cu-ATSM albumin binding arises from interaction(s) with the IIA site of HSA.

KW - Albumin

KW - Distribution

KW - PET

KW - Preclinical pharmacokinetics

KW - Protein binding

UR - http://www.scopus.com/inward/record.url?scp=67049109385&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67049109385&partnerID=8YFLogxK

U2 - 10.1002/jps.21570

DO - 10.1002/jps.21570

M3 - Article

VL - 98

SP - 2170

EP - 2179

JO - Journal of Pharmaceutical Sciences

JF - Journal of Pharmaceutical Sciences

SN - 0022-3549

IS - 6

ER -